Table 1.
Characteristics of the T2DM participants in the sarcopenia group and control group stratified by sex.
| Men | Women | |||||||
|---|---|---|---|---|---|---|---|---|
| Control group | Sarcopenia group | t/X2/Z | P | Control group | Sarcopenia group | t/X2/Z | P | |
| N | 291 | 295 | 429 | 110 | ||||
| Age (years) | 60.3 ± 7.4 | 64.6 ± 9.3 | -6.139 | ≤0.001 | 62.1 ± 7.2 | 64.9 ± 9.1 | -3.017 | 0.003 |
| BMI (kg/m2) | 26.2 ± 3.4 | 25.3 ± 3.3 | 3.252 | 0.001 | 26.0 ± 3.2 | 25.6 ± 3.5 | 1.057 | 0.291 |
| <25 | 119 (40.9%) | 150(50.8%) | 177 (41.3%) | 49 (44.5%) | ||||
| 25-30 | 135 (46.4%) | 123(41.7%) | 209 (48.7%) | 49 (44.5%) | ||||
| ≥30 | 37 (12.7%) | 22(7.5%) | 43 (10.0%) | 12 (10.9%) | ||||
| Waist-to-hip ratio | 0.93 ± 0.06 | 0.92 ± 0.07 | 1.963 | 0.050 | 0.93 ± 0.06 | 0.92 ± 0.06 | 1.956 | 0.051 |
| Diabetes duration (years) | 10.0 (5.1, 15.4) | 10.6 (5.5, 17.8) | -1.850 | 0.064 | 10.2 (5.2, 15.2) | 11.2 (6.0, 15.7) | -1.722 | 0.085 |
| Current smoker, n (%) | 108 (37.2%) | 101 (34.2%) | 0.575 | 0.448 | 12 (2.8%) | 5 (4.5%) | 0.876 | 0.349 |
| Current drinker, n (%) | 157 (54%) | 125 (42.4%) | 7.867 | 0.005 | 32 (7.5%) | 4 (3.6%) | 2.053 | 0.152 |
| Hypertension, n (%) | 173 (59.5%) | 188 (63.7%) | 1.134 | 0.287 | 236 (55.0%) | 67 (60.9%) | 1.237 | 0.266 |
| Coronary heart disease, n (%) | 49 (16.8%) | 58 (19.7%) | 0.782 | 0.377 | 65 (15.2%) | 26 (23.6%) | 4.492 | 0.034 |
| Peripheral neuropathy, n (%) | 107 (36.8%) | 154 (52.2%) | 14.126 | ≤0.001 | 178 (41.5%) | 45 (40.9%) | 0.012 | 0.912 |
| Diabetic nephropathy, n (%) | 93 (32.0%) | 134 (45.4%) | 11.192 | 0.001 | 133(31.0%) | 34(30.9%) | ≤0.001 | 0.985 |
| Oral hypoglycemic agents, n (%) | 221 (75.9%) | 201 (68.1%) | 4.433 | 0.035 | 323 (75.3%) | 91 (82.9%) | 2.718 | 0.099 |
| Insulin treatment, n (%) | 104 (35.7%) | 151 (51.2%) | 14.222 | ≤0.001 | 164 (38.2%) | 40 (36.4%) | 0.129 | 0.719 |
Notes: data were expressed as the mean ± standard deviation or % and median (25th–75th percentile).